International reimbursement levels revealed in Canadian industry report
This article was originally published in Scrip
Executive Summary
The Canadian pharmaceutical industry association, Rx&D, has published a report ranking OECD countries according to their public reimbursement of 150 innovative medicines (representing 181 indications in Canada), finding that Canada ranks 23 out of 29 countries, far behind the OECD average.